BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35203557)

  • 1. The Alternative RelB NF-kB Subunit Exerts a Critical Survival Function upon Metabolic Stress in Diffuse Large B-Cell Lymphoma-Derived Cells.
    Nuan-Aliman S; Bordereaux D; Thieblemont C; Baud V
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.
    Eluard B; Nuan-Aliman S; Faumont N; Collares D; Bordereaux D; Montagne A; Martins I; Cagnard N; Caly M; Taoui O; Lordello L; Lehmann-Che J; Tesson B; Martinez-Climent JA; Copie-Bergman C; Haioun C; Tilly H; Bonsang B; Vincent-Salomon A; Jais JP; Jardin F; Leroy K; Maiuri MC; Kroemer G; Molina TJ; Feuillard J; Baud V
    Blood; 2022 Jan; 139(3):384-398. PubMed ID: 34232979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
    Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
    J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-κB pathway.
    Ramachandiran S; Adon A; Guo X; Wang Y; Wang H; Chen Z; Kowalski J; Sunay UR; Young AN; Brown T; Mar JC; Du Y; Fu H; Mann KP; Natkunam Y; Boise LH; Saavedra HI; Lossos IS; Bernal-Mizrachi L
    Int J Cancer; 2015 May; 136(10):2341-51. PubMed ID: 25359525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.
    Zhang M; Xu-Monette ZY; Li L; Manyam GC; Visco C; Tzankov A; Wang J; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Pham LV; Young KH
    Aging (Albany NY); 2016 Dec; 8(12):3321-3340. PubMed ID: 27941215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.
    Pham LV; Fu L; Tamayo AT; Bueso-Ramos C; Drakos E; Vega F; Medeiros LJ; Ford RJ
    Blood; 2011 Jan; 117(1):200-10. PubMed ID: 20889926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
    Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
    Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NF-κB fingerprinting reveals heterogeneous NF-κB composition in diffuse large B-cell lymphoma.
    Jayawant E; Pack A; Clark H; Kennedy E; Ghodke A; Jones J; Pepper C; Pepper A; Mitchell S
    Front Oncol; 2023; 13():1181660. PubMed ID: 37333821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
    Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
    Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines.
    Hailfinger S; Nogai H; Pelzer C; Jaworski M; Cabalzar K; Charton JE; Guzzardi M; Décaillet C; Grau M; Dörken B; Lenz P; Lenz G; Thome M
    Proc Natl Acad Sci U S A; 2011 Aug; 108(35):14596-601. PubMed ID: 21873235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
    Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
    J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells.
    Kim SW; Oleksyn DW; Rossi RM; Jordan CT; Sanz I; Chen L; Zhao J
    Blood; 2008 Feb; 111(3):1644-53. PubMed ID: 18025152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD40 ligand-mediated activation of the de novo RelB NF-kappaB synthesis pathway in transformed B cells promotes rescue from apoptosis.
    Mineva ND; Rothstein TL; Meyers JA; Lerner A; Sonenshein GE
    J Biol Chem; 2007 Jun; 282(24):17475-85. PubMed ID: 17446175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells.
    Lwin T; Hazlehurst LA; Li Z; Dessureault S; Sotomayor E; Moscinski LC; Dalton WS; Tao J
    Leukemia; 2007 Jul; 21(7):1521-31. PubMed ID: 17476277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A roadmap of constitutive NF-κB activity in Hodgkin lymphoma: Dominant roles of p50 and p52 revealed by genome-wide analyses.
    de Oliveira KA; Kaergel E; Heinig M; Fontaine JF; Patone G; Muro EM; Mathas S; Hummel M; Andrade-Navarro MA; Hübner N; Scheidereit C
    Genome Med; 2016 Mar; 8(1):28. PubMed ID: 26988706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) induces apoptosis of human diffuse large B-cell lymphoma cells through a peroxisome proliferator-activated receptor gamma-independent pathway.
    Ray DM; Morse KM; Hilchey SP; Garcia TM; Felgar RE; Maggirwar SB; Phipps RP; Bernstein SH
    Exp Hematol; 2006 Sep; 34(9):1202-11. PubMed ID: 16939813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
    Davis RE; Brown KD; Siebenlist U; Staudt LM
    J Exp Med; 2001 Dec; 194(12):1861-74. PubMed ID: 11748286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of heme oxygenase-1 induced by constitutively activated NF-κB as a potential therapeutic target for activated B-cell-like diffuse large B-cell lymphoma.
    Huang J; Guo P; Ma D; Lin X; Fang Q; Wang J
    Int J Oncol; 2016 Jul; 49(1):253-64. PubMed ID: 27211510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.
    Kloo B; Nagel D; Pfeifer M; Grau M; Düwel M; Vincendeau M; Dörken B; Lenz P; Lenz G; Krappmann D
    Proc Natl Acad Sci U S A; 2011 Jan; 108(1):272-7. PubMed ID: 21173233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A.
    Pulvino M; Liang Y; Oleksyn D; DeRan M; Van Pelt E; Shapiro J; Sanz I; Chen L; Zhao J
    Blood; 2012 Aug; 120(8):1668-77. PubMed ID: 22791293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.